Perforated balloon technique mediated intracoronary delivery of nicorandil to treat coronary no-reflow phenomenon: a novel pharmacological solution to precarious situation.
Perforated balloon technique
TIMI flow
TIMI frame count
nicorandil
no-reflow
percutaneous coronary intervention
Journal
American journal of cardiovascular disease
ISSN: 2160-200X
Titre abrégé: Am J Cardiovasc Dis
Pays: United States
ID NLM: 101569582
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
03
2021
accepted:
23
08
2021
entrez:
1
12
2021
pubmed:
2
12
2021
medline:
2
12
2021
Statut:
epublish
Résumé
Coronary no-reflow (NRF) following percutaneous coronary intervention (PCI) is infrequent but one of the most dreaded complication which results from impaired flow of microvascular bed. It is associated with adverse outcome if flow is not restored. Objective of this study was to find safety, effectiveness and outcome of intracoronary nikorandil (IC) administered using perforated balloon technique (PBT) to reverse NRF. 2-4 mg of nicorandil was diluted with 5 ml of normal saline and administered using PBT over 5-minute. Its effectiveness was evaluated after 10 minute qualitatively using TIMI flow and quantitatively corrected TIMI frame count (cTFC) method. Study comprised of 84 patients (out of 1789 patients undergoing PCI between January 2019 and February 2020). Their mean age was 57.8±17.9 years. Following PBT, TIMI III flow was successfully normalized in 71 subjects (84.5%), ten (12%) patients had TIMI II flow and it was not successful in three (3.5%) patients. TIMI flow grade got bettered from 1.03 to 2.58 and cTIMI frame count regressed from 52.9±11 to 16.5±5 (P < 0.001). PBT was well tolerated except short lived drop in blood pressure (n=10; 11.9%). This study, for the first time to the best our knowledge, demonstrated that PBT mediated intracoronary administration of nikorandil distally was rapid, safe, and efficacious method to deal with NRF.
Sections du résumé
BACKGROUND
BACKGROUND
Coronary no-reflow (NRF) following percutaneous coronary intervention (PCI) is infrequent but one of the most dreaded complication which results from impaired flow of microvascular bed. It is associated with adverse outcome if flow is not restored. Objective of this study was to find safety, effectiveness and outcome of intracoronary nikorandil (IC) administered using perforated balloon technique (PBT) to reverse NRF.
METHOD
METHODS
2-4 mg of nicorandil was diluted with 5 ml of normal saline and administered using PBT over 5-minute. Its effectiveness was evaluated after 10 minute qualitatively using TIMI flow and quantitatively corrected TIMI frame count (cTFC) method.
RESULT
RESULTS
Study comprised of 84 patients (out of 1789 patients undergoing PCI between January 2019 and February 2020). Their mean age was 57.8±17.9 years. Following PBT, TIMI III flow was successfully normalized in 71 subjects (84.5%), ten (12%) patients had TIMI II flow and it was not successful in three (3.5%) patients. TIMI flow grade got bettered from 1.03 to 2.58 and cTIMI frame count regressed from 52.9±11 to 16.5±5 (P < 0.001). PBT was well tolerated except short lived drop in blood pressure (n=10; 11.9%).
CONCLUSION
CONCLUSIONS
This study, for the first time to the best our knowledge, demonstrated that PBT mediated intracoronary administration of nikorandil distally was rapid, safe, and efficacious method to deal with NRF.
Types de publication
Journal Article
Langues
eng
Pagination
544-554Informations de copyright
AJCD Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
Circulation. 1987 Apr;75(4):817-29
pubmed: 3103950
Circulation. 2002 Feb 5;105(5):656-62
pubmed: 11827935
Circulation. 2008 Jun 17;117(24):3152-6
pubmed: 18559715
Cathet Cardiovasc Diagn. 1998 Dec;45(4):360-5
pubmed: 9863736
Am Heart J. 2000 May;139(5):824-9
pubmed: 10783216
J Am Coll Cardiol. 1999 Mar;33(3):654-60
pubmed: 10080465
Indian Heart J. 2016 Jul-Aug;68(4):539-51
pubmed: 27543480
Am Heart J. 2003 Jan;145(1):42-6
pubmed: 12514653
Am J Cardiol. 1995 Apr 15;75(12):849-50
pubmed: 7717298
Heart. 2006 Sep;92(9):1278-84
pubmed: 16449518
Exp Clin Cardiol. 2008 Fall;13(3):141-3
pubmed: 19343130
Catheter Cardiovasc Interv. 2004 Apr;61(4):484-91
pubmed: 15065143
J Invasive Cardiol. 1997 May;9(4):270-273
pubmed: 10762911
Catheter Cardiovasc Interv. 2000 Sep;51(1):27-31; discussion 32
pubmed: 10973014
Circulation. 1996 Mar 1;93(5):879-88
pubmed: 8598078
Circ J. 2002 Dec;66(12):1119-23
pubmed: 12499617
Circ Cardiovasc Interv. 2009 Aug;2(4):323-9
pubmed: 20031735
Exp Ther Med. 2015 Sep;10(3):1059-1065
pubmed: 26622439
Cardiovasc Ultrasound. 2015 May 27;13:26
pubmed: 26012474
Catheter Cardiovasc Interv. 2002 Dec;57(4):444-51
pubmed: 12455077
Catheter Cardiovasc Interv. 2005 Nov;66(3):327-32
pubmed: 16208711
Circ Cardiovasc Interv. 2010 Feb 1;3(1):27-33
pubmed: 20118156
Catheter Cardiovasc Interv. 2018 Nov 1;92(5):890-894
pubmed: 29280545
J Invasive Cardiol. 2010 Mar;22(3):125-9
pubmed: 20197580
Med Sci Monit. 2017 Jun 15;23:2924-2930
pubmed: 28617765
Cathet Cardiovasc Diagn. 1996 Oct;39(2):113-8
pubmed: 8922307
Med Sci Monit. 2018 May 04;24:2767-2776
pubmed: 29726480
Circulation. 2004 Mar 9;109(9):1121-6
pubmed: 14967718
J Am Coll Cardiol. 2000 Oct;36(4):1202-9
pubmed: 11028471
J Am Coll Cardiol. 2005 Jun 7;45(11):1775-80
pubmed: 15936605
JACC Cardiovasc Interv. 2013 Jun;6(6):580-9
pubmed: 23683738
J Am Coll Cardiol. 1985 Mar;5(3):587-92
pubmed: 3156171
J Interv Cardiol. 2010 Apr;23(2):109-13
pubmed: 20337859
Tex Heart Inst J. 2008;35(4):439-46
pubmed: 19156238